- ISIN
- US67577R1023
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 23, 2005
Highlights
- Market Cap
- $3.55B
- Enterprise Value
- $3.49B
- EPS (TTM)
- -$0.26
- Total Revenue (TTM)
- $9.83M
- Gross Profit (TTM)
- $3.78M
- EBITDA (TTM)
- -$52.07M
- Year Range
- $0.90 - $5.81
- Target Price
- $7.67
- ROA (TTM)
- -160.11%
- ROE (TTM)
- 233.29%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
IRD Performance Chart
Opus Genetics, Inc (IRD) is up 103.0% since the beginning of the year. At $4 per share, IRD is trading 29.8% below its 52-week high of $6. Investors who bought $1,000 worth of IRD shares 5 years ago would now be looking at an investment worth $845.
Loading charts...
Returns By Period
Opus Genetics, Inc (IRD) has returned 102.99% so far this year and 329.43% over the past 12 months. Over the last ten years, IRD has returned -28.97% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Opus Genetics, Inc
- 1D
- 0.25%
- 1M
- -4.23%
- YTD
- 102.99%
- 6M
- 98.06%
- 1Y
- 329.43%
- 3Y*
- 1.43%
- 5Y*
- -3.32%
- 10Y*
- -28.97%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
IRD Monthly Returns History
Based on dividend-adjusted daily data since May 23, 2005, IRD's average daily return is +0.11%, while the average monthly return is +0.49%. At this rate, an investment would double in approximately 11.8 years.
Historically, 41% of months were positive and 59% were negative. The best month was Jan 2014 with a return of +125.5%, while the worst month was Aug 2019 at -57.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 8 months.
On a daily basis, IRD closed higher 40% of trading days. The best single day was May 12, 2009 with a return of +111.6%, while the worst single day was Apr 13, 2010 at -51.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 14.93% | 80.09% | 9.38% | 12.31% | -14.68% | -6.42% | 102.99% | ||||||
| 2025 | -6.72% | -7.21% | -4.68% | -3.24% | 4.68% | -5.27% | 17.82% | 9.91% | 35.25% | 39.39% | -7.39% | -5.63% | 68.91% |
| 2024 | -12.96% | -3.24% | -20.71% | -21.14% | 5.99% | -8.93% | 30.07% | -37.69% | 5.65% | -8.40% | -7.50% | 7.21% | -60.47% |
| 2023 | -1.70% | -0.58% | 8.70% | 36.80% | -24.76% | 12.44% | -0.23% | -7.85% | -16.04% | -14.93% | 7.02% | -1.31% | -14.73% |
| 2022 | -15.01% | 7.89% | -5.26% | -27.78% | -9.40% | -9.43% | -2.60% | 21.39% | -11.45% | 16.92% | 31.06% | 14.61% | -5.36% |
| 2021 | 79.82% | -9.08% | -45.24% | -12.39% | -10.81% | 16.30% | -20.45% | 5.95% | 15.73% | -23.50% | -0.76% | -4.60% | -42.53% |
Benchmark Metrics
Opus Genetics, Inc has an annualized alpha of 18.29%, beta of 1.08, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since May 23, 2005.
- This stock participated in 134.28% of S&P 500 Index downside but only -17.58% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 18.29%
- Beta
- 1.08
- R²
- 0.04
- Upside Capture
- -17.58%
- Downside Capture
- 134.28%
Return for Risk
Risk / Return Rank
IRD ranks 96 for risk / return — in the top 96% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Opus Genetics, Inc (IRD) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| IRD | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.61 | ||
| Sortino ratioReturn per unit of downside risk | +1.40 | ||
| Omega ratioGain probability vs. loss probability | 1.49 | 1.37 | +0.12 |
| Calmar ratioReturn relative to maximum drawdown | 10.26 | 2.78 | +7.48 |
| Martin ratioReturn relative to average drawdown | 26.22 | 12.44 | +13.78 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Opus Genetics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Opus Genetics, Inc was 99.98%, occurring on Apr 11, 2025. The portfolio has not yet recovered.
The current Opus Genetics, Inc drawdown is 99.86%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -99.98%Apr 2025 | 16y 10mo | — | 18y 1moMay 2008 - now |
2007 bear market2007 | -78.00%Feb 2007 | 4mo 13d | 1y 3mo | 1y 8moSep 2006 - May 2008 |
2006 bear market2006 | -75.00%Jun 2006 | 10mo 5d | 2mo 3d | 1y 3dAug 2005 - Aug 2006 |
2005 bear market2005 | -37.50%May 2005 | 3d | 2mo 3d | 2mo 6dMay 2005 - Jul 2005 |
Drawdown Indicators
| IRD | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.98% | -56.78% | -43.20% |
Max Drawdown (1Y)Largest decline over 1 year | -32.35% | -9.10% | -23.25% |
Max Drawdown (3Y)Largest decline over 3 years | -83.68% | -18.90% | -64.78% |
Max Drawdown (5Y)Largest decline over 5 years | -88.89% | -25.43% | -63.46% |
Max Drawdown (10Y)Largest decline over 10 years | -99.78% | -33.92% | -65.86% |
Current DrawdownCurrent decline from peak | -99.86% | -1.80% | -98.06% |
Average DrawdownAverage peak-to-trough decline | -87.69% | -10.71% | -76.98% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.64% | 2.03% | +10.61% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Opus Genetics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Opus Genetics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for IRD relative to other companies in the Biotechnology industry. Currently, IRD has a P/S ratio of 168.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with IRD
Add Opus Genetics, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with IRD